Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 301–400 of 1,012
Patorno, E., Gopalakrishnan, C., Franklin, J. M., Brodovicz, K. G., Masso‐Gonzalez, E., Bartels, D. B., Liu, J., & Schneeweiss, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13184 · Cited by 84
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 85
“Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha(1-67) in patients with type 2 diabetes.”
BackgroundDiabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality
Milazzo, V., Cosentino, N., Genovese, S., Campodonico, J., Mazza, M., Metrio, M. D., & Marenzi, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_481 · Cited by 98
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials
Deacon, C. F. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13135 · Cited by 81
“glycaemic control, the low frequency of hypoglycaemia events and the good tolerability in patients aged 70 years and above(107) reflect what is seen in the younger patients typically recruited in phase 3 trials (average age: 55-65 years), while sub-group analyses of the completed CV safety outcome trials also confirm…”
ResultIncretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
Faillie, J.-L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., & Suissa, S. (2014) · BMJ · doi:10.1136/bmj.g2780 · Cited by 83
McGurnaghan, S. J., Blackbourn, L. A. K., Mocevic, E., Panton, U. H., McCrimmon, R. J., Sattar, N. A., Wild, S. H., & Colhoun, H. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13825 · Cited by 87
“Trials of the DPP-4 inhibitors sitagliptin [14], alogliptin [15] and saxagliptin [16] have not shown these reductions.”
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Filippatos, T. D., Athyros, V. G., & Elisaf, M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.907274 · Cited by 95
“In the EXAMINE trial, which randomized 5380 patients with T2DM and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 -- 90 days to alogliptin or placebo on top of existing antihyperglycemic and cardiovascular drug therapy for up to 40 months (median 18 months), t…”
BackgroundMethodGarg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
Booth, G. L., Lipscombe, L. L., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., Simpson, S. H., et al. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.09.003 · Cited by 90
Cardiovascular outcome trials of glucose-lowering medications: an update
Home, P. (2019) · Diabetologia · doi:10.1007/s00125-018-4801-1 · Cited by 82
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
Zhong, J., & Rajagopalan, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00477 · Cited by 83
“Several recent large scale clinical trials have indicated that unlike most other oral anti-diabetic drugs that promote cardiovascular disease, DPP4 inhibitors are safe from cardiovascular standpoint despite lack of evidence showing beneficial effect (96) (97) (98) .”
BackgroundRosenstock, J., Marx, N., Neubacher, D., Seck, T., Patel, S., Woerle, H.-J., & Johansen, O. E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0215-2 · Cited by 82
“This finding would need to be further evaluated, in particular because similar results were not observed in the recent SAVOR-TIMI 53 and EXAMINE trials [12-14].”
InfluentialNyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12889 · Cited by 84
“Sulphonylurea 3763 (30) 7113 (28) 3405 (31) 3431 (32) .”
Tang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13232 · Cited by 78
Rosenstock, J., Perkovic, V., Alexander, J. H., Cooper, M. E., Marx, N., Pencina, M. J., Toto, R. D., Wanner, C., Zinman, B., Baanstra, D., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0682-3 · Cited by 83
“The three DPP-4 inhibitors studied to date (saxagliptin [6], alogliptin [7], sitagliptin [8]) have demonstrated neutral effects on atherosclerotic CV disease.”
BackgroundThe Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Kim, N.-H., Yu, T., & Lee, D. H. (2014) · BioMed Research International · doi:10.1155/2014/368703 · Cited by 94
Johnston, R., Uthman, O. A., Cummins, E., Clar, C., Royle, P., Colquitt, J. L., Tan, B. K., Clegg, A. J., Shantikumar, S., Court, R. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21020 · Cited by 92
“l EXAMINE for alogliptin (Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome).(141) l TECOS for sitagliptin (Trial Evaluating Cardiovascular Outcomes with Sitagliptin).”
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Sesti, G., Avogaro, A., Belcastro, S., Bonora, B. M., Croci, M., Daniele, G., Dauriz, M., Dotta, F., Formichi, C., Frontoni, S., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-018-1271-3 · Cited by 94
Marfella, R., Sardu, C., Calabrò, P., Siniscalchi, M., Minicucci, F., Signoriello, G., Balestrieri, M. L., Mauro, C., Rizzo, M. R., Paolisso, G., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13122 · Cited by 80
“GLP-1 levels (active GLP-1 [7-36] specific ELISA kit; Epitope Diagnostics, San Diego, California) were measured after an overnight fast (at 8:00 AM) and after breakfast in patients with diabetes.”
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 124
An update on DPP-4 inhibitors in the management of type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257608 · Cited by 83
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Fisher, M., Petrie, M. C., Ambery, P., Donaldson, J., Ye, J., & McMurray, J. J. V. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00233-8 · Cited by 85
Zhang, Z., Chen, X., Lu, P., Zhang, J., Xu, Y., He, W., Li, M., Zhang, S., Jia, J., Shao, S., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0512-z · Cited by 78
“Six randomized controlled trials met our selection criteria and were included in this meta-analysis: EXamination of cArdiovascular outcomes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) [30, 31], the”
MethodInfluentialNelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw182 · Cited by 78
“The work was significantly increased in MIþMK-0626þVe mice compared to the MIþNDþVe mice, and this was completely inhibited in the MIþMK-0626þ Ex-(9-39) (GLP-1 receptor antagonist) mice (respectively, P< 0.”
BackgroundMethodInfluentialZhao, H., Wei, R., Wang, L., Tian, Q., Tao, M., Ke, J., Liu, Y., Hou, W., Zhang, L., Yang, J., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2014 · Cited by 77
“However, data from two recent large cardiovascular end-point trials of dipeptidyl peptidase-4 inhibitors, saxagliptin and alogliptin, have shown no significant differences between the treatment and placebo groups in the incidence of pancreatic cancer (31, 39).”
ResultSGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. M., & Inzucchi, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0943-4 · Cited by 87
Worsening Heart Failure During the Use of DPP-4 Inhibitors
Packer, M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.12.016 · Cited by 86
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 123
Hiruma, S., Shigiyama, F., Hisatake, S., Mizumura, S., Shiraga, N., Hori, M., Ikeda, T., Hirose, T., & Kumashiro, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01228-3 · Cited by 87
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
Brenner, C., Franz, W.-M., Kühlenthal, S., Kuschnerus, K., Remm, F., Gross, L., Theiss, H. D., Landmesser, U., & Kränkel, N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.044 · Cited by 83
“Initial clinical trials in diabetic patients were not able to verify a significant benefit of gliptin treatment on survival of diabetic patients [28, 29], while the majority of animal studies maintains a reduction of atherosclerotic burden in murine models treated with various gliptins [3–6,26].”
BackgroundResultRecomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 87
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 77
“Noteworthy, the T2D population included in each of these outcome trials was different: if in TECOS, these subjects were with an established CVD, in SAVOR TIMI they had a history or were at risk for CVD and lastly, in EXAMINE they had an acute coronary syndrome within the previous 15–90 days [46, 47, 52].”
BackgroundMethodHigh glucose–induced endothelial progenitor cell dysfunction
Kang, H., Ma, X., Liu, J., Fan, Y., & Deng, X. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117719058 · Cited by 82
Al-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
Meagher, P., Adam, M., Civitarese, R., Bugyei‐Twum, A., & Connelly, K. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.026 · Cited by 85
Yamada, H., Tanaka, A., Kusunose, K., Amano, R., Matsuhisa, M., Daida, H., Ito, M., Tsutsui, H., Nanasato, M., Kamiya, H., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0546-2 · Cited by 76
“Alogliptin in the EXAMIN [11], saxagliptin in the SAVOR-TIMI 53 [12], and sitagliptin in the TECOS [13] all showed non-inferior to placebo to lower the risk of the composite primary endpoint of CV death, myocardial infarction or ischemic stroke.”
MethodCardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
“3A) and, when reported, on HHF (Additional file 1: Table S1) [23, 31, 34, 96].”
BackgroundInfluentialMorgan, C. L., Mukherjee, J., Jenkins‐Jones, S., Holden, S. E., & Currie, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12306 · Cited by 86
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 78
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 74
“While in the ELIXA and TECOS trials there is no specification of the type of renal events [44], in EXAMINE only initiation of dialysis is reported [47].”
MethodBell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 87
Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 72
“In the first two adequately powered clinical outcome trials of the effects of DPP-4 inhibitors on CVD events, neutral effects on CVD events were reported with alogliptin in patients with type 2 diabetes after acute coronary syndrome (45) and with saxagliptin in patients with type 2 diabetes who had a history of or wer…”
BackgroundLevelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 84
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., & Chaiyakunapruk, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.146 · Cited by 72
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 82
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72
“However, recently completed, appropriately designed, phase III trials with the intent of demonstrating benefit from a CV perspective have not shown significant improvement in primary CV endpoints in patients treated with DPP4i compared to placebo [4, 5] .”
BackgroundMarx, N., McGuire, D. K., Perkovic, V., Woerle, H.-J., Broedl, U. C., von Eynatten, M., George, J. T., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dc17-0068 · Cited by 72
Cardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 80
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
“DPP4- inhibitors Alogliptin 12·5, 25 mg QD Proven CV safety in population of patients with recent ACS EXAMINE [83]”
BackgroundOverbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“The full texts of the remaining studies were evaluated for the inclusion and exclusion criteria, which resulted in a final inclusion of 25 studies.(2,3,17-39) For 4 studies, the authors were contacted, because the publications did not contain sufficient information regarding risk or variables needed to calculate the r…”
BackgroundEffects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 78
Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study
Gokhale, M., Buse, J. B., Gray, C. L., Pate, V., Marquis, M. A., & Stürmer, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12379 · Cited by 72
“of DPP-4 inhibitors were reported [12,13].”
Ou, H., Chang, K., Li, C., & Wu, J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0350-4 · Cited by 73
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 80
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 84
Svanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 71
Giorda, C. B., Sacerdote, C., Nada, E., Marafetti, L., Baldi, I., & Gnavi, R. (2014) · Endocrine · doi:10.1007/s12020-014-0386-8 · Cited by 75
Chang, C., Yeh, Y., Chan, Y., Liu, J., Chang, S., Lee, H., Wu, L., Yen, K., Kuo, C.-T., & See, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0640-5 · Cited by 81
“SAVOR-TIMI53, and TECOS, all failed to show significant improvement in cardiovascular outcomes in type 2 diabetic patients treated with DPP4i [38, 42, 43].”
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 81
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70
Clemens, K. K., Woodward, M., Neal, B., & Zinman, B. (2020) · Diabetes Care · doi:10.2337/dc19-2257 · Cited by 70
“Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (18,26,27).”
BackgroundBirnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 72
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D., Church, R., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 67
“In this regard, it should be noted that the first large-scale GLP-1 cardiovascular trials recently reported that the DPP-4 inhibitors, saxagliptin and alogliptin, did not confer cardiovascular benefit in type 2 diabetes [61, 62], although there are currently no data from long-term randomised clinical trials with GLP-1…”
BackgroundSavarese, G., D’Amore, C., Federici, M., Martino, F. D., Dellegrottaglie, S., Marciano, C., Ferrazzano, F., Losco, T., Lund, L. H., Trimarco, B., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.208 · Cited by 76
“However, in the EXAMINE trial [8], enrolling 5,380 patients with type 2 DM, with either acute MI or unstable angina requiring hospitalization within the previous 15 to 90 days, who were randomized to Alogliptin or placebo, no significant differences in the primary outcome (CV death, MI and stroke), or in the single co…”
MethodLiu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 76
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.010 · Cited by 74
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 73
Zhao, M. H., Chen, J., Yuan, Y., Zou, Z., Lai, X., Rahmani, D. M., Wang, F., Yang, X., Huang, Q., & Bu, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-07921-2 · Cited by 77
Wu, H., Xu, L., Zhao, X., Zhang, H., Cheng, K., Wang, X., Chen, M., Li, G., Huang, J., Lan, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062762 · Cited by 71
DPP-4 inhibitors: pharmacological differences and their clinical implications
Ceriello, A., Sportiello, L., Rafaniello, C., & Rossi, F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.944862 · Cited by 75
Esposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Capuano, A., & Giugliano, D. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005442 · Cited by 68
Oyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., Kamiya, H., Ajioka, M., Ishihara, M., Dai, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002051 · Cited by 73
Pasternak, B., Wintzell, V., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 69
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
Pujadas, G., Nigris, V. D., Prattichizzo, F., Sala, L. L., Testa, R., & Ceriello, A. (2016) · Endocrine · doi:10.1007/s12020-016-1052-0 · Cited by 70
Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., et al. (2016) · Diabetes · doi:10.2337/db15-0122 · Cited by 65
“Data from the more recent and superiorly designed studies Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) (73) and EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMIN…”
MethodRaz, I., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Scirica, B. M., Umez-Eronini, A., Im, K., Stahre, C., Buskila, A., Iqbal, N., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2546 · Cited by 66
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 71
Devin, J. K., Pretorius, M., Nian, H., Yu, C., Billings, F. T., & Brown, N. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02767 · Cited by 67
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
“Safety studies, which have been of relatively short duration, have failed to demonstrate special ASCVD benefits by DPP-4 inhibitors [60–62].”
BackgroundCavender, M. A., White, W. B., Jarolím, P., Bakris, G. L., Cushman, W. C., Kupfer, S., Gao, Q., Mehta, C. R., Zannad, F. M., Cannon, C. P., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024632 · Cited by 71
Self-citationRoussel, R., Steg, P. G., Mohammedi, K., Marre, M., & Potier, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13033 · Cited by 66
Weng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T. (2019) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.76 · Cited by 65
Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
Patel, D. M., Bose, M., & Cooper, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062218 · Cited by 71
“The EXAMINE trial did not find any difference in eGFR or incidence of initiation of dialysis with the use of alogliptin compared with placebo [305].”
BackgroundHanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
Ke, J., Pan, J., Lin, H., & Gu, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14224 · Cited by 70
“SAVOR-TIMI 53 trial may be independent of the drug-class effect of DPP-4 inhibitors.(150) Anyway, the role of DPP-4 in-”
Fu, J., Zhu, J., Hao, Y.-H., Guo, C., & Zhou, Z. (2016) · Scientific Reports · doi:10.1038/srep29104 · Cited by 67
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, C., & Marx, N. (2018) · Diabetologia · doi:10.1007/s00125-018-4678-z · Cited by 65
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.